Gonitro Patent Expiration

Gonitro is a drug owned by G Pohl Boskamp Gmbh And Co Kg. It is protected by 1 US drug patent filed in 2016 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 11, 2032. Details of Gonitro's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101592 Stabilized granules containing glyceryl trinitrate
Mar, 2032

(7 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Gonitro's patents.

Given below is the list of recent legal activities going on the following patents of Gonitro.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 31 Jan, 2023 US9101592
Payment of Maintenance Fee, 4th Year, Large Entity 31 Jan, 2019 US9101592
Application ready for PDX access by participating foreign offices 31 Aug, 2015 US9101592
Recordation of Patent Grant Mailed 11 Aug, 2015 US9101592
Patent Issue Date Used in PTA Calculation 11 Aug, 2015 US9101592
Email Notification 23 Jul, 2015 US9101592
Issue Notification Mailed 22 Jul, 2015 US9101592
Dispatch to FDC 10 Jul, 2015 US9101592
Application Is Considered Ready for Issue 10 Jul, 2015 US9101592
Issue Fee Payment Received 01 Jul, 2015 US9101592

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Gonitro is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Gonitro's family patents as well as insights into ongoing legal events on those patents.

Gonitro's Family Patents

Gonitro has patent protection in a total of 7 countries. It's US patent count contributes only to 26.3% of its total global patent coverage. Click below to unlock the full patent family tree for Gonitro.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Gonitro's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 11, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Gonitro Generics:

Nitroglycerin is the generic name for the brand Gonitro. 25 different companies have already filed for the generic of Gonitro, with Mylan Technologies having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Gonitro's generic

Alternative Brands for Gonitro

There are several other brand drugs using the same active ingredient (Nitroglycerin) as Gonitro. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Abbvie
Rectiv
Evus
Nitromist
Pohl Boskamp
Nitrolingual Pumpspray
Viatris
Nitrostat


Apart from brand drugs containing the same ingredient, some generics have also been filed for Nitroglycerin, Gonitro's active ingredient. Check the complete list of approved generic manufacturers for Gonitro





About Gonitro

Gonitro is a drug owned by G Pohl Boskamp Gmbh And Co Kg. Gonitro uses Nitroglycerin as an active ingredient. Gonitro was launched by Pohl Boskamp in 2016.

Approval Date:

Gonitro was approved by FDA for market use on 08 June, 2016.

Active Ingredient:

Gonitro uses Nitroglycerin as the active ingredient. Check out other Drugs and Companies using Nitroglycerin ingredient

Dosage:

Gonitro is available in powder form for sublingual use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.4MG/PACKET POWDER Discontinued SUBLINGUAL